

PENDING

MMA-CME/CPD
MPS-CPD



NATIONAL CANCER CONGRESS MALAYSIA

Bridging Gaps, Building Hope, Empowering Lives

NATIONAL CANCER CONGRESS MALAYSIA 2026

FIRST ANNOUNCEMENT

Date: 4 - 6 September 2026

Time: 8:00 AM - 5:00 PM

Venue: Sunway University, Kuala Lumpur

Organised by:



BRIDGING GAPS, BUILDING HOPE, EMPOWERING LIVES

The National Cancer Society of Malaysia and Sunway University are pleased to organise the National Cancer Congress Malaysia (NCCM) 2026, building on the success of NCCM 2024 and NCCM 2025.

Held from 4 to 6 September 2026 at Sunway University, Kuala Lumpur, NCCM 2026 will bring together healthcare professionals, researchers, policymakers and advocates under the theme, “Bridging Gaps, Building Hope, Empowering Lives.”

The congress will explore the full cancer care continuum, including prevention, screening, diagnosis, treatment, survivorship, advocacy and policy. Through plenary and scientific sessions, expert speakers will share research, insights and best practices to advance cancer care in Malaysia.

We invite you to join the discussions, exchange ideas and build meaningful connections at NCCM 2026.

THE COMMITTEES

Steering Committee

- Prof. Dr Rosmawati Mohamed
- Prof. Dr Abhimanyu Veerakumarasivam
- Prof. Dr Elil Renganathan
- Dr Noraryana binti Hassan
- Dato’ Dr Saunthari Somasundaram
- Prof. Dr Raja Affendi Raja Ali

Scientific Committee

- Prof. Dr Felicia Chung Fei Lei
- Dr Lau Tze Pheng

Organising Committee

- Kolonel Bersekutu (PA)
Prof. Dr Murallitharan Munisamy

IMPORTANT DATES

**15 JUNE
2026**

**Abstract
Submission
Opens**

**14 AUGUST
2026**

**Abstract
Submission
Closes**

**10 AUGUST
2026**

**Abstract
Withdrawal
Closes**

REGISTRATION RATES

RM 150

Abstract Presenters

** For the first 50 pax only*

** Abstracts accepted by the Scientific Committee*

**Bursaries
Available**

RM 300

Subsidised fee applicable for:

- Students
- Government agencies (e.g. Ministry of Health)
- University / Academic personnel
- Partner institutions

**Partner Institutions are listed in:
<https://nccm.cancer.org.my/partner-institutions/>

**Malaysian
Delegate**

RM 3,900

(HRD Corp Claimable)

- Open to all Malaysian delegates
- For HRDC registration, kindly email at training@cancer.org.my to request for:
 - Course content
 - Trainer profiles
 - Quotation

**International
Delegate**

USD 1,400

- Open to all international delegates

Time/Track	Track 1	Track 2	Track 3	Track 4
8:00am - 9:00am	Registration			
9:00am - 10:00am	Breakfast, networking, and booth exhibition			
Theme	KEYNOTE PANEL Cancer control: are we solving the right problems?			
10:00am - 10:20am	1. The clinical front line: why are cancers still being diagnosed late?			
10:20am - 10:40am	2. From policy to practice: Is the cancer system delivering?			
10:40am - 11:00am	3. The patient journey: where—and why—are people being left behind?			
11:00am - 11:30am	Panel discussion			
Theme	PREVENTION From understanding risk to taking action: what can each part of society contribute?			
Sub-Theme	Tobacco and emerging cancer risks: where should Malaysia act first?	Biomedical breakthroughs in cancer prevention: vaccine-preventable and infection-related cancers	Structural and commercial drivers of cancer risk: Who must act—and how can we reach those most affected?	Emerging levers and partnerships: Which new approaches can move prevention from pilots to scale?
11:30am - 11:50am	Which risks contribute most to Malaysia's preventable cancer burden—and where should action start?	HPV and cervical cancer prevention: connecting vaccination, screening and treatment — lessons from Malaysia and the region	Unequal risk, unequal protection: how do geography, income, work and service design shape cancer prevention opportunities?	Weight management and cancer prevention: what can lifestyle support, medicines or digital tools and healthier products realistically achieve?
11:50am - 12:10pm	Tobacco control in action: which evidence-based policies should Malaysia strengthen?	From hepatitis control to liver cancer prevention: progress, implementation and priorities in Malaysia and the region	Closing governance gaps: who is accountable for cancer prevention across healthcare, government, and commercial sectors?	Exploring financial incentives for prevention: how might insurance benefits and wellness programmes support participation and uptake?
12:10pm - 12:30pm	Cleaner environments and safer workplaces: how can policy, employers and industry reduce air pollution, occupational exposure and environmental carcinogens?	<i>H. pylori</i> and gastric cancer prevention: what would an effective detection, treatment and follow-up pathway look like?	Building trust in cancer prevention: what shapes community acceptance of—or resistance to—prevention interventions?	Beyond healthcare: how can government, workplaces, schools, industry, civil society and communities build responsible partnerships to scale cancer prevention?
12:30pm - 1:00pm	Panel Q&A	Panel Q&A	Panel Q&A	Panel Q&A
1:00pm - 2:30pm	Lunch, Friday prayer, networking, and booth exhibition			
2:30pm - 4:00pm	Opening ceremony of National Cancer Congress Malaysia 2026			
4:00pm - 5:30pm	Coffee break, networking, and booth exhibition			

Time/Track	Track 1	Track 2	Track 3	Track 4
8:00am - 9:00am	Registration			
9:00am - 10:00am	Breakfast, Networking, and Booth Exhibition			
Theme	SCREENING AND DIAGNOSIS Why are cancers still being diagnosed late—and what will help us detect them earlier?			
Theme	From screening eligibility to confirmed diagnosis: how can we keep every patient on the pathway?	Making cancer screening work in practice: how can we expand access, improve quality, and increase uptake?	The future of detection: where can liquid biopsy, AI and emerging applications add real clinical value?	Rare and younger-onset cancers: are our data, detection and care pathways keeping pace?
10:00am - 10:20am	Who should be screened? Translating risk-based eligibility and recommendations into practice	Bringing screening closer to communities: can mobile services and point-of-care testing expand access?	Liquid biopsy and multicancer early detection: where can these tests add value—and where is evidence still needed?	Rare cancers in Malaysia: what do current trends, clinical experience, emerging research and the JARANG registry reveal?
10:20am - 10:40am	From self-sampling and laboratory testing to diagnosis: how do we build a complete screening pathway?	Closing the [breast/lung cancer/cervical/NPC] screening gap: lessons from Malaysian programmes and studies	Evaluating emerging detection technologies: what evidence is needed on accuracy, clinical utility, overdiagnosis and patient benefit?	Adolescent, young-adult and early-onset cancers in Malaysia: what do incidence patterns and emerging evidence tell us?
10:40am - 11:00am	From abnormal result to confirmed diagnosis: what should clinicians, laboratories and screening programmes do next?	Financing screening and diagnostic assessment before cancer is confirmed: how can insurance, employer support and public-private partnerships reduce barriers?	AI-assisted detection and diagnostic imaging: how should Malaysia validate and implement these tools safely?	Adapting detection and referral pathways for rare and younger-onset cancers: what needs to change?
11:00am - 11:30am	Panel Q&A	Panel Q&A	Panel Q&A	Panel Q&A
Theme	FROM DIAGNOSIS TO TREATMENT How can evidence and innovation lead to faster, more precise and more equitable care?			
Theme	New frontiers in cancer diagnosis: can better testing improve treatment decisions?	Innovation and affordability: how should Malaysia fund cancer treatment?	From bench to Malaysian bedside: how can evidence and innovation translate into better care?	The discovery pipeline: basic science in Malaysian cancer research
11:30am - 11:50am	From biopsy to tumour profile: how can pathology, biomarkers and molecular testing provide the information clinicians need?	Assessing value: how should clinical benefit, cost and budget impact be evaluated?	Real-world cancer treatment in Malaysia: what do registry and routine-care data reveal about effectiveness and gaps?	Cancer models identified in Malaysia

Time/Track	Track 1	Track 2	Track 3	Track 4
11:50am - 12:10pm	From test result to treatment decision: how can biomarkers and integrated diagnostics guide the right treatment for the right patient?	Making funding decisions: how should Malaysia set priorities and decide what to reimburse?	Bringing innovation into Malaysian cancer care: how can workforce, referral and implementation barriers be addressed?	The local drug-discovery and development pipeline: what is ready to move forward?
12:10pm - 12:30pm	Innovation for whom? Can advanced diagnostic technologies be affordable, scalable and equitable?	Improving access now: what funding and patient-access programmes are available, and where are the remaining gaps?	Integrating palliative care alongside treatment: what should trigger referral, and how can earlier support improve quality of life?	Malaysian cancer-vaccine research: progress and future directions
12:30pm - 1:00pm	Panel Q&A	Panel Q&A	Panel Q&A	Panel Q&A
1:00pm - 2:30pm	Lunch, networking, and booth exhibition			
Theme	TREATMENT If cancer treatment is advancing rapidly, why do outcomes remain unequal?			
Theme	Mechanisms of drug resistance: why do treatments stop working—and what can we do next?	From genome to treatment: cancer genomics in Malaysia	Why do patients not complete—or benefit fully from—treatment?	Right treatment, right intensity: how do we avoid overtreating some patients and undertreating others?
2:30pm - 2:50pm	What does treatment resistance look like, and how can clinicians recognise it earlier?	What are local cancer-genomics studies revealing about actionable alterations and treatment response?	Clinical barriers to treatment completion: toxicity, complications, and treatment-related burden	Risk stratification and shared decision-making: how do we decide who needs more, less or different treatment?
2:50pm - 3:10pm	The cellular and molecular basis of acquired resistance: which mechanisms are most clinically relevant and actionable?	Does ancestry matter? What do Malaysian and regional data suggest about treatment response and toxicity?	Supporting patients through treatment: how can nutrition/rehabilitation /psychosocial care improve treatment tolerance?	Tools for treatment escalation and de-escalation: how can biomarkers, genomic tests and clinical decision-support tools guide treatment intensity?
3:10pm - 3:30pm	What comes after progression? How can rebiopsy, combination strategies and adaptive treatment approaches overcome resistance?	From genomic discovery to clinical action: how can findings become treatment targets, trials and companion diagnostics for patients?	Beyond clinical care: how do adherence, transport, caregiving and financial strain affect treatment outcomes?	Practice variation and quality: how can Malaysia reduce low-value care and promote appropriate treatment?
3:30pm - 4:00pm	Panel Q&A	Panel Q&A	Panel Q&A	Panel Q&A
4:00pm - 5:00pm	Oral rapid fire presentation			
5:00pm - 5:30pm	Coffee break, networking, and booth exhibition			

Time/Track	Track 1	Track 2	Track 3	Track 4
8:00am - 9:00am	Registration			
9:00am - 10:00am	Breakfast, Networking, and Booth Exhibition			
Theme	SURVIVORSHIP Beyond treatment: are we prepared for what comes next?			
Theme	Quality of life, peer support and returning to normal life	Life after cancer: body, identity and fear of recurrence	Circle of care after treatment	Late effects and secondary cancers
10:00am - 10:20am	From treatment to survivorship: how can clinicians prepare patients for life after treatment and support better quality of life?	Rebuilding after treatment: where are the gaps in rehabilitation and mental-health support for survivors?	Who should lead survivorship care: oncology, primary care or a shared-care model?	Late effects after cancer treatment: what should clinicians recognise, monitor and manage?
10:20am - 10:40am	Returning to everyday life after cancer: how can patient navigation, return-to-work support and financial assistance reduce the financial burden on survivors?	Fertility, sexual health and body image after cancer: how can services respond more effectively?	Supporting caregivers beyond treatment: what practical support can reduce caregiver burden?	Secondary cancers and long-term outcomes: what do registry and real-world data tell us?
10:40am - 11:00am	The survivor's voice: what does life after active cancer treatment really feel like?	Scanxiety and fear of recurrence: what helps survivors cope with ongoing uncertainty?	The caregiver voice: how can families be included in survivorship planning without overlooking their own needs?	Living beyond cancer: perspectives on late effects, secondary cancer risks and long-term follow-up
11:00am - 11:30am	Panel Q&A	Panel Q&A	Panel Q&A	Panel Q&A
11:30am - 1:00pm	Closing ceremony of National Cancer Congress Malaysia 2026			
1:00pm - 2:30pm	Lunch, networking, and booth exhibition			

KEY HIGHLIGHTS

1

Presentations by national and international leading cancer experts

Hear leading national and international cancer experts share the latest insights and advances across the cancer care continuum.



2



Rapid-fire presentations

Discover emerging research and innovations through concise, engaging presentations by selected abstract presenters.

3

Insightful plenaries by leading international experts

Gain fresh perspectives on global developments and their implications for the future of cancer care in Malaysia.



4



Industry exhibition

Explore the latest technologies, services and solutions from leading healthcare organisations and industry partners.

5

Networking opportunities

Connect with healthcare professionals, researchers and industry leaders to exchange ideas and build meaningful collaborations.





JOIN US FOR THE NATIONAL CANCER CONGRESS MALAYSIA 2026

SCAN HERE TO REGISTER!



**BRIDGING GAPS, BUILDING HOPE,
EMPOWERING LIVES**